title: Efficacy and safety of febuxostat in patients with hyperuricemia and gout.
abstract: The past decade has witnessed an exponential increase of novel therapeutic modalities for a variety of rheumatic disorders, including gout. During the past few years two novel therapeutic agents have been approved by the US Food and Drug Administration for the treatment of hyperuricemia in patients with gout, one of them being febuxostat, a nonpurine selective inhibitor of xanthine oxidase. Review of its pharmacokinetics and pharmacodynamics, efficacy and safety profile, and use in gout patients with comorbid conditions reveals that age and gender have no clinically significant effect and dose adjustments based on age or gender are not required. In addition, febuxostat can be used in patients with mild-to-moderate renal or hepatic involvement. Its overall efficacy and safety profile is comparable and, in certain subsets such as gout patients with mild and moderate renal insufficiency, is superior to allopurinol.
authors.affiliation: Section of Rheumatology, Department of Medicine, LSU Health Science Center, New Orleans, LA, USA.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Garcia-Valladares
authors.forename: Tahir
authors.initials: T
authors.lastname: Khan
authors.forename: Luis R
authors.initials: LR
authors.lastname: Espinoza